# Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

> **NCT01188863** · PHASE1 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 15 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** 300 mg LX4211 (150 mg tablets)
- **DRUG:** 300 mg LX4211 (50 mg tablets)
- **DRUG:** 300 mg LX4211 (liquid)

## Key facts

- **NCT ID:** NCT01188863
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2011-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188863, "Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01188863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*